Can-Fite BioPharma
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 5
- Market Cap
- $12.2M
- Website
- http://www.canfite.com
- Introduction
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-...
FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer
The FDA granted orphan drug designation to namodenoson for pancreatic cancer treatment. Namodenoson, targeting A3AR on cancer cells, induces apoptosis and is safe due to A3AR's low expression on normal cells. A phase 2 study is planned to evaluate its safety and clinical activity. Preclinical studies showed significant dose-dependent inhibition of pancreatic cancer cell growth and modulation of signaling pathways, supporting further evaluation.
Related Clinical Trials:
FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer
Can-Fite BioPharma's oncology drug candidate, Namodenoson, granted Orphan Drug Designation by the FDA for pancreatic cancer. The company plans to start a Phase II study in pancreatic cancer by the end of the year.
Hepatocellular Carcinoma Clinical Trials 2024: EMA, PDMA, FDA
DelveInsight's 'Hepatocellular Carcinoma Pipeline Insight 2024' report details 90+ companies developing 95+ pipeline drugs for HCC, with therapies in various stages of clinical development, including collaborations and regulatory approvals.
© Copyright 2024. All Rights Reserved by MedPath